Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Chief Financial Officer | April 22, 2026 | April 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date April 22, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,905 |
Last balance in matching sequence
After 2026-04-22 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-04-22 · Sale · Disposed 3,208 · Balance 172,792 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Partial disposition of shares to satisfy tax withholding obligations. F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 2 · 2026-04-22 · Sale · Disposed 1,157 · Balance 171,635 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Partial disposition of shares to satisfy tax withholding obligations. F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 3 · 2026-04-22 · Sale · Disposed 8,730 · Balance 162,905 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Partial disposition of shares to satisfy tax withholding obligations. F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: Partial disposition of shares to satisfy tax withholding obligations.
F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2026 Filed Apr 24, 2026 22:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,730 | $71.92 | $627,861.60 |
DisclosureSEC source: 0000879407-26-000039 · wk-form4_1777070680.xml · nonDerivative · entry 3 Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,905 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · shares: Partial disposition of shares to satisfy tax withholding obligations. F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,157 | $70.45 | $81,510.65 |
DisclosureSEC source: 0000879407-26-000039 · wk-form4_1777070680.xml · nonDerivative · entry 2 Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,635 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · shares: Partial disposition of shares to satisfy tax withholding obligations. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,208 | $70.11 | $224,912.88 |
DisclosureSEC source: 0000879407-26-000039 · wk-form4_1777070680.xml · nonDerivative · entry 1 Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,792 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · shares: Partial disposition of shares to satisfy tax withholding obligations. F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002081169-26-000002 · wk-form4_1767915947.xml · nonDerivative · entry 1 Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,200 F1 · shares: Represents shares underlying restricted stock units which will vest in four equal annual installments. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.